Literature DB >> 17918079

A step closer to extreme drug resistance (XDR) in gram-negative bacilli.

David L Paterson, Yohei Doi.   

Abstract

Mesh：

Year:  2007        PMID： 17918079     DOI： 10.1086/522287

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  44 in total

1.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

2.  Evaluation of CpxRA as a Therapeutic Target for Uropathogenic Escherichia coli Infections.

Authors:  Lana Dbeibo; Julia J van Rensburg; Sara N Smith; Kate R Fortney; Dharanesh Gangaiah; Hongyu Gao; Juan Marzoa; Yunlong Liu; Harry L T Mobley; Stanley M Spinola
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

Review 3.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

4.  Polymyxin-resistant clinical isolates of Escherichia coli.

Authors:  Carl Urban; Hemavarna Tiruvury; Noriel Mariano; Rita Colon-Urban; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

5.  In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.

Authors:  Andrea Endimiani; Gopi Patel; Kristine M Hujer; Mahesh Swaminathan; Federico Perez; Louis B Rice; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

6.  KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.

Authors:  Ji-Young Rhee; Young Kyoung Park; Joo Yeon Shin; Ji Young Choi; Mi Young Lee; Kyong Ran Peck; Jae-Hoon Song; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

Review 7.  Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.

Authors:  Marin H Kollef; Yoav Golan; Scott T Micek; Andrew F Shorr; Marcos I Restrepo
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

Review 8.  Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Brad Spellberg; George Talbot
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

9.  Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients.

Authors:  C Peña; S Gómez-Zorrilla; C Suarez; M A Dominguez; F Tubau; O Arch; A Oliver; M Pujol; J Ariza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-04       Impact factor: 3.267

10.  Extensively drug-resistant Acinetobacter baumannii.

Authors:  Yohei Doi; Shahid Husain; Brian A Potoski; Kenneth R McCurry; David L Paterson
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.